Skip to main content
Fig. 3 | Diabetology & Metabolic Syndrome

Fig. 3

From: Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

Fig. 3

Cumulative incidence curves of limb outcomes and composite renal outcomes of SGLT2i versus DPP4i (after PSM) among patients with T2D who had undergone PAD revascularization. Cumulative incidence curves of specified outcomes of SGLT2i versus DPP4i (after PSM) among patients with T2D who had undergone PAD revascularization: a repeated revascularization, b lower limb amputation, c and composite renal outcomes are presented. Compared with DPP4i, SGLT2i were associated with comparable cumulative risks of repeated revascularization and lower limb amputation but a lower cumulative risk of composite renal outcomes. Other abbreviations are the same as those in Figs. 1 and 2

Back to article page